122,18 €
1,66 %heute
L&S, 29. Februar, 18:54 Uhr
ISIN
US64125C1099
Symbol
NBIX
Berichte
Sektor
Industrie

Neurocrine Biosciences, Inc. Aktie News

Neutral
MCAP MediaWire
etwa 3 Stunden alt
New York, N.Y., February 29, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million Americans.
Neutral
PRNewsWire
2 Tage alt
TD Cowen 44th Annual Healthcare Conference on March 5 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami Barclays 26th Annual Global Healthcare Conference on March 13 in Miami SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in March. Matt Abernethy, Chief Financial Officer, and...
Positiv
Investors Business Daily
6 Tage alt
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positiv
Seeking Alpha
19 Tage alt
Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntington's chorea and long-term care facilities) and prepare the market for the eventual crinecerfont launch. Neurocrine has a number of Phase II read-out...
Neutral
Seeking Alpha
22 Tage alt
Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript
Neutral
PRNewsWire
22 Tage alt
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29% Respectively INGREZZA® (valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion Crinecerfont FDA Regulatory Submission Anticipated in the Second Quarter for the Treatment of Congenital Adrenal Hyperplasia in Adults...
Neutral
PRNewsWire
etwa ein Monat alt
Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO , Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
Neutral
PRNewsWire
etwa 2 Monate alt
SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen